Novel investigational biologics for the treatment of cancer cachexia

Bibliography

• Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2(11):862-71
   PubMed Web of Science ®Google Scholar
• Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44(8):1124-32
   PubMed Web of Science ®Google Scholar
• von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1(1):1-5
   PubMed Web of Science ®Google Scholar
• Utech AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 2012;3(4):245-51
   PubMed Web of Science ®Google Scholar
• Farkas J, von Haehling S, Kalantar-Zadeh K, et al. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle 2013;4(3):173-8
   Google Scholar
• Laine A, Iyengar P, Pandita TK. The role of inflammatory pathways in cancer-associated cachexia and radiation resistance. Mol Cancer Res 2013;11(9):967-72
   PubMed Web of Science ®Google Scholar
• Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008;27(6):793-9
   PubMed Web of Science ®Google Scholar
• Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006;83(6):1345-50
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr 2010;29(2):154-9
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12(5):489-95
   PubMed Web of Science ®Google Scholar
• Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer 2013;21(6):1569-77
   PubMed Web of Science ®Google Scholar
• Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69(4):491-7
   PubMed Web of Science ®Google Scholar
• Tuca A, Jimenez-Fonseca P, Gascon P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol 2013;88(3):625-36
   PubMed Web of Science ®Google Scholar
• Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50(5):889-96
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15(8):2920-6
   PubMed Web of Science ®Google Scholar
• Bachmann J, Heiligensetzer M, Krakowski-Roosen H, et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008;12(7):1193-201
   PubMed Web of Science ®Google Scholar
• Mariani L, Lo Vullo S, Bozzetti F. Weight loss in cancer patients: a plea for a better awareness of the issue. Support Care Cancer 2011;20(2):301-9
   PubMed Web of Science ®Google Scholar
• Martignoni ME, Kunze P, Friess H. Cancer cachexia. Mol Cancer 2003;2:36
   PubMedGoogle Scholar
• Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia–pathophysiology and management. J Gastroenterol 2013;48(5):574-94
   PubMed Web of Science ®Google Scholar
• Blum D, Omlin A, Baracos VE, et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol 2011;80(1):114-44
   PubMed Web of Science ®Google Scholar
• Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 2011;62:265-79
   PubMed Web of Science ®Google Scholar
• Nicolini A, Ferrari P, Masoni MC, et al. Malnutrition, anorexia and cachexia in cancer patients: a mini-review on pathogenesis and treatment. Biomed Pharmacother 2013;67(8):807-17
   PubMed Web of Science ®Google Scholar
• Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 2011;668(Suppl 1):S81-6
   PubMed Web of Science ®Google Scholar
• Seelaender M, Batista M Jr, Lira F, et al. Inflammation in cancer cachexia: to resolve or not to resolve (is that the question?). Clin Nutr 2012;31(4):562-6
   PubMed Web of Science ®Google Scholar
• Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998;25(2 Suppl 6):53-7
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccio A, Lai P, et al. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998;25(2 Suppl 6):45-52
   PubMed Web of Science ®Google Scholar
• Songur N, Kuru B, Kalkan F, et al. Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 2004;90(2):196-200
   PubMed Web of Science ®Google Scholar
• Staal-van den Brekel AJ, Dentener MA, Schols AM, et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995;13(10):2600-5
   PubMed Web of Science ®Google Scholar
• Bayliss TJ, Smith JT, Schuster M, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011;11(12):1663-8
   PubMed Web of Science ®Google Scholar
• Clarke SJ, Gebbie C, Sweeney C, et al. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Cachexia Sarcopenia Muscle 2010;1:98
   Google Scholar
• Clarke SJ, Smith JT, Gebbie C, et al. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol (2009 ASCO Annual Meeting Proceedings) 2009;27(15S):3025
   Google Scholar
• Rigas JR, Schuster M, Orlov SV, et al. Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial. J Clin Oncol(2010 ASCO Annual Meeting Abstracts) 2010;28(15):7622
   Google Scholar
• Schuster M, Rigas JR, Orlov SV, et al. ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial. J Clin Oncol (2010 ASCO Annual Meeting Abstracts) 2010;28(15):7631
   Google Scholar
• Clinical trial activities. Available from: http://www.xbiotech.com/clinical/clinical-trial-activity.html [Last accessed 11 December 2013]
   Google Scholar
• A study using MABp1 to increase overall survival in patients with colorectal cancer and weight loss. Available from: http://clinicaltrials.gov/ct2/show/NCT01767857?term=MABp1&rank=1 [Last accessed 11 December 2013]
   Google Scholar
• Baracos VE. Clinical trials of cancer cachexia therapy, now and hereafter. J Clin Oncol 2013;31(10):1257-8
   PubMed Web of Science ®Google Scholar
• Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003;21(1):129-34
   PubMed Web of Science ®Google Scholar
• Del Fabbro E, Dev R, Hui D, et al. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol 2013;31(10):1271-6
   PubMed Web of Science ®Google Scholar
• Paspaliaris V, Langan B, DeAndrea R, et al. Phase I/II study of IP-1510 a novel interleukin-1 receptor antagonist in the management of cancer-related cachexia. J Cachexia Sarcopenia Muscle 2011;2:261
   Google Scholar
• Chasen MR, Bhargava R, Hirschman SZ, Taraporewala I. Phase II study of OHR/AVR118 in anorexia-cachexia. J Cachexia Sarcopenia Muscle 2013;4:335
   Google Scholar
• Chasen MR, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid AVR118 in the management of cancer-related anorexia/cachexia. J Cachexia Sarcopenia Muscle 2010;2010(1):98
   Google Scholar
• D'Olimpio JT, Chasen MR, Sharma R, et al. Phase II study of AVR118 in the management of cancer related anorexia/cachexia. J Clin Oncol (2009 ASCO Annual Meeting Proceedings) 2009;27(15S):e20631
   Google Scholar
• McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387(6628):83-90
   PubMed Web of Science ®Google Scholar
• Roth SM, Walsh S. Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care 2004;7(3):259-63
   PubMed Web of Science ®Google Scholar
• Thomas M, Langley B, Berry C, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 2000;275(51):40235-43
   PubMed Web of Science ®Google Scholar
• Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011;2(3):143-51
   PubMed Web of Science ®Google Scholar
• Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98(16):9306-11
   PubMed Web of Science ®Google Scholar
• Aversa Z, Bonetto A, Penna F, et al. Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 2012;19(4):1350-6
   PubMed Web of Science ®Google Scholar
• Bonetto A, Penna F, Aversa Z, et al. Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. Muscle Nerve 2013;48(3):387-92
   PubMed Web of Science ®Google Scholar
• Lokireddy S, Wijesoma IW, Bonala S, et al. Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J 2012;446(1):23-36
   PubMedGoogle Scholar
• Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 2013, doi:10.1128/MCB.01307-13
   PubMed Web of Science ®Google Scholar
• Clinical study of BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas. Available from: http://clinicaltrials.gov/ct2/show/NCT01433263?term=BYm338&rank=6 [Last accessed 11 December 2013]
   Google Scholar
• Bauerlein R, Pangilinan J, Salzler R, et al. Efficacy of REGN1033, a fully human anti-myostatin antagonist antibody, in rodent muscle function. J Cachexia Sarcopenia Muscle 2013;4:331
   Google Scholar
• A study to access the safety and tolerability of single ascending doses of REGN1033(SAR391786). Available from: http://clinicaltrials.gov/ct2/results?term=regn1033&Search=Search [Last accessed 11 December 2013]
   Google Scholar
• Lieffers JR, Mourtzakis M, Hall KD, et al. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 2009;89(4):1173-9
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33(5):997-1006
   PubMed Web of Science ®Google Scholar